Oxaliplatin Pharmacokinetics and Pharmacodynamics in Three Metastatic Colorectal Cancer Patients with HemodialysisOsawa H*
Department of Oncology and Hematology, Edogawa Hospital, Tokyo, Japan
- *Corresponding Author:
- Hiroshi Osawa
Department of Oncology and Hematology
Edogawa Hospital, 2-24-18 Higashi-koiwa
Edogawa, Tokyo 1330052, Japan
E-mail: [email protected]
Received date: October 18, 2016; Accepted date: November 14, 2016; Published date: November 17, 2016
Citation: Osawa H (2016) Oxaliplatin Pharmacokinetics and Pharmacodynamics in Three Metastatic Colorectal Cancer Patients with Hemodialysis. J Mol Genet Med 10:234 doi:10.4172/1747-0862.1000234
Copyright: © 2016 Osawa H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Aim: We investigated the safety and feasibility of L-OHP with chronic renal failure (CRF) on hemodialysis (HD) patients by examining the influence of pharmacokinetics and pharmacodynamics of oxaliplatin (L-OHP). Furthermore, we investigated.
Methods: We present the results of three patients who were treated with modified FOLFOX6 (mFOLFOX6) chemotherapy for a mCRC with chronic renal failure on HD. We measured their plasma concentration of total platinum and free platinum. We evaluated whether L-OHP dose could be safely used for these patients. Different starting dose of L-OHP and 5-fluorouracil (50% and 75%) were used in these patients. Pharmacokinetics monitoring of platinum in plasma, plasma ultrafiltrates were measured these time schedule follow as: pre-chemotherapy infusion and 4 hours (pre-HD), 6 hours (half of HD), 8 hours (post HD), 48 hours after.
Results: The 50% of peak concentrations (Cmax) was 0.27 μgã»hr/mL ± 0.02 μg/mL and 75% Cmax was 0.41 μgã»hr/mL ± 0.02 μg/mL. 50% of the area under the concentration versus time curve (AUC) was 14.8 μgã»hr/mL ± 1.22 μgã»hr/mL and 75% AUC was 22.43 μgã»hr/mL ± 0.85 μgã»hr/mL.
Conclusion: We recognized these free plasma concentration which 50% dose of L-OHP was similar AUC between healthy and CRF patients. L-OHP pharmacokinetics and pharmacodynamics are altered in patients with CRF, but corresponding increase in L-OHP related hematological and non-hematological toxicities is not observed. It is important for cancer patients with CRF that the feasibility and efficacy of L-OHP combined chemotherapy should be determined.